TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02135250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xinkeshu tablets
Description: 4 Xinkeshu tablets are given three times per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: the placebo is not drug.
Study: NCT01054014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527/Placebo
Description: Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527/Placebo
Description: JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527
Description: JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
Study: NCT02474316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180ug/wk s.c for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nucleos(t)ide analgoue
Description: nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nucleos(t)ide analgoue
Description: nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
Study: NCT01874002

Intervention type: DEVICE
Intervention: Combo stent
Description: Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
Study: NCT01521117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Use 1 capsule (5 mg) once per day for first 21 days than 10mg qday for 21 days.
Study: NCT03773640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio frequency currents
Description: Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sonophoresis
Description: The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
Study: NCT00437112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: patient specific dose, injectable, before meals, 24 weeks
Study: NCT01394237

Intervention type: OTHER
Intervention: Examination
Description: Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
Study: NCT01269203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 1000 mg per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered daily same as Curcumin.
Study: NCT02575963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Phase 1 only)
Description: Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lintuzumab-Ac225
Description: In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide (Phase 1 only)
Description: 40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
Study: NCT02743208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short stem hip arthroplasty (SHA)
Description: Furlong Evolution femoral stem

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty (THA)
Description: Furlong H-A.C. femoral stem
Study: NCT03690193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, \<10% carbohydrate, and 20% protein).
Study: NCT01065844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: 1250 mg Nelfinavir twice daily Monday - Sunday
Study: NCT02046967

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation with 940 nm bare fiber
Description: Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous steam ablation with steam vein sclerosis system.
Description: Endovenous steam ablation with steam vein sclerosis.
Study: NCT03558737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high-frequency jet ventilation (nHFJV)
Description: Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Description: Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
Study: NCT04663763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Sintilimab is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor. Usage: 200mg ivgtt d1 q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Usage: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Usage: 130mg/m2 d1 q3w
Study: NCT03025282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD10367 3% Solution - Non-desquamated zone
Description: Once daily application for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD10367 1% Solution - Non-desquamated zone
Description: Once daily application for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD10367 solution placebo - Non-desquamated zone
Description: Once daily application for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betneval ointment - Non-desquamated zone
Description: Once daily application for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD10367 3% Solution - Desquamated zone
Description: Once daily application for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD10367 solution placebo - Desquamated zone
Description: Once daily application for 3 weeks
Study: NCT00392327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study: NCT02197559

Intervention type: PROCEDURE
Intervention: DES group
Description: all the participants in this group will be performed with drug -eluting stents

Intervention type: PROCEDURE
Intervention: BMS group
Description: all the participants in this group will be performed with bare-metal stents
Study: NCT03768583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM ICT sneakers
Description: Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM ICT barefoot
Description: Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM health sneaker
Description: Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
Study: NCT00392327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03768583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group TSM health barefoot
Description: Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
Study: NCT04201964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of tenecteplase
Description: Intra-arterial administration of tenecteplase (0.2-0.4 mg/min) immediately after thrombectomy device pass for 30-40 minutes.
Study: NCT00392327

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03469947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 gram of prehospital Tranexamic Acid
Study: NCT00534612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aspiration biopsy
Description: fine needle aspiration biopsy of the parotid gland masses
Study: NCT02205736

Intervention type: OTHER
Group type: OTHER
Intervention: Breast Health Education
Description: Small group breast health educational sessions for Latino women in home setting.
Study: NCT00896402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin antisepsis with chlorhexidine
Description: Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine
Description: Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
Study: NCT01066013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial de-escalation strategy
Description: The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
Study: NCT05056935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB1148
Description: A total of 700 mL of LB1148 will be administered orally as a split dose before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Study: NCT04065269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: ATR inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 immunotherapy
Study: NCT01849263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03534804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is administered at 40 mg oral daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
Study: NCT02581085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol (TCT)
Description: TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control study capsule that includes no study product (Vitamin E - Tocotrienol)
Study: NCT04451525

Intervention type: DEVICE
Intervention: MicroVention Mechanical Thrombectomy Devices as first-line treatment
Description: Patient will be treated with mechanical thrombectomy at the direction of the treating physician

Intervention type: DEVICE
Intervention: MicroVention Mechanical Thrombectomy Devices as first-line treatment
Description: Patient will be treated with mechanical thrombectomy at the direction of the treating physician
Study: NCT03659188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cortico-alveolar perforations
Description: Mechanical drills will be used on a handpiece

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Corticotomy
Description: Piezo-surgery will be employed following flaps' elevation.
Study: NCT02569385

Intervention type: OTHER
Intervention: Spontaneous breathing trial
Study: NCT02078206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive stimulation
Study: NCT01400308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin + Chlorhexidin
Description: Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prontoderm MRSA Kit
Description: Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device
Study: NCT02658526

Intervention type: BEHAVIORAL
Intervention: anesthesia - surgery

Intervention type: BEHAVIORAL
Intervention: anesthesia - surgery
Study: NCT00681460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human recombined insulin
Description: multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
Study: NCT02486718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplatin 75 milligrams per square meter (mg/m\^2) IV on Day 1 of up to four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Participants will receive vinorelbine 30 mg/m\^2 IV on Days 1 and 8 of each of the four 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 mg/m\^2 IV on Day 1 of each of the four 21-day cycles.
Study: NCT06502912

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02440451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback using BCI
Description: This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
Study: NCT01543932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
Study: NCT00658684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
Study: NCT01468467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Oral Liquid